Prognosis of Chronic Spontaneous Urticaria with an Inadequate Response to Omalizumab

Overview

Journal Int J Dermatol

Specialty Dermatology

Date 2024 Nov 3

PMID 39489861

Authors

Haruka Watanabe

Shunsuke Takahagi

Koremasa Hayama

Atsushi Fukunaga

Yukinobu Nakagawa

Naoko Inomata

Yuko Chinuki

Michihiro Hide

Affiliations

Soon will be listed here.

Abstract

Background: Chronic spontaneous urticaria (CSU) exhibits notable responsiveness to omalizumab (OMA). The prognosis and subsequent therapeutic strategies warrant comprehensive exploration in cases exhibiting inadequate responses to OMA.

Methods: We conducted a multicenter retrospective analysis to investigate the 12-month prognosis of patients inadequately responding to three injections of OMA. The endpoints encompassed identifying predictive factors for a favorable prognosis and assessing interventions related to an ameliorated prognostic outlook.

Results: The study involved 48 patients who met the inclusion criteria. After three OMA administrations, therapeutic interventions included the continuation of OMA in 34 patients, systemic corticosteroids in seven patients, and immunosuppressants in 12 patients. After 12 months, 28 of the 48 patients exhibited a good prognosis, whereas the remaining 20 displayed a less favorable prognosis. Good prognostic determinants encompassed the duration of CSU within 51 weeks, the presence of angioedema, IgE levels ≤100 IU/mL pre-OMA, blood eosinophil counts ≥100/mm post-OMA, and urticaria control test (UCT) scores ≥5 pre-OMA and ≥6 post-OMA. Following the third OMA injection, the implementation of immunosuppressants presented an association with a good prognosis, while the employment of systemic corticosteroids correlated with an unfavorable prognosis.

Conclusions: More than half of patients inadequately responding to OMA achieved a good prognosis 12 months later. Several clinical variables appear to be predictive of prognosis, and certain therapeutic agents can be associated with prognostic outcomes.

Citing Articles

Navigating Non-Response: Prognosis and Strategies in Chronic Spontaneous Urticaria Management.

Kocaturk E, Zuberbier T Int J Dermatol. 2025; 64(2):227-228.

PMID: 39783877 PMC: 11771634. DOI: 10.1111/ijd.17653.

References

Grattan C, ODonnell B, Francis D, Niimi N, Barlow R, Seed P . Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol. 2000; 143(2):365-72. DOI: 10.1046/j.1365-2133.2000.03664.x. View

Kaplan A, Ferrer M, Bernstein J, Antonova E, Trzaskoma B, Raimundo K . Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2015; 137(2):474-81. DOI: 10.1016/j.jaci.2015.08.023. View

Oliver E, Sterba P, Saini S . Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria. Allergy. 2015; 70(5):601-3. DOI: 10.1111/all.12578. View

Maurer M, Khan D, Elieh Ali Komi D, Kaplan A . Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. J Allergy Clin Immunol Pract. 2021; 9(3):1067-1078. DOI: 10.1016/j.jaip.2020.11.043. View

Matsubara D, Takahagi S, Saito R, Kamegashira A, Tanaka A, Hide M . Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria. J Dermatol. 2020; 48(1):56-63. DOI: 10.1111/1346-8138.15630. View

Saito R, Takahagi S, Nakano F, Furutani K, Mihara S, Numata T . A survey on subtypes and clinical characteristics of 1061 patients with urticaria in the primary care institutes in Japan. J Dermatol. 2022; 49(12):1255-1262. DOI: 10.1111/1346-8138.16562. View

Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M . Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016; 175(6):1153-1165. DOI: 10.1111/bjd.14768. View

Takahagi S, Kamegashira A, Fukunaga A, Inomata N, Nakahara T, Hayama K . Real-world clinical practices for spontaneous urticaria and angioedema in Japan: A nation-wide cross-sectional web questionnaire survey. Allergol Int. 2019; 69(2):300-303. DOI: 10.1016/j.alit.2019.10.003. View

Kozel M, Mekkes J, Bossuyt P, Bos J . Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001; 45(3):387-91. DOI: 10.1067/mjd.2001.116217. View

10.

Bernstein J, Kavati A, Tharp M, Ortiz B, MacDonald K, Denhaerynck K . Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence. Expert Opin Biol Ther. 2018; 18(4):425-448. DOI: 10.1080/14712598.2018.1438406. View

11.

Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet P, Bousquet J . Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2010; 66(3):317-30. DOI: 10.1111/j.1398-9995.2010.02496.x. View

12.

Turk M, Carneiro-Leao L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M . How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers. J Allergy Clin Immunol Pract. 2019; 8(1):113-124. DOI: 10.1016/j.jaip.2019.07.021. View

13.

Weller K, Groffik A, Church M, Hawro T, Krause K, Metz M . Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014; 133(5):1365-72, 1372.e1-6. DOI: 10.1016/j.jaci.2013.12.1076. View

14.

Huang A, Chichester K, Saini S . Association of basophil parameters with disease severity and duration in chronic spontaneous urticaria (CSU). J Allergy Clin Immunol Pract. 2019; 8(2):793-795.e6. PMC: 7012729. DOI: 10.1016/j.jaip.2019.08.004. View

15.

Vena G, Cassano N, Colombo D, Peruzzi E, Pigatto P . Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006; 55(4):705-9. DOI: 10.1016/j.jaad.2006.04.078. View

16.

Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A . The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017; 72(12):2005-2016. PMC: 5724512. DOI: 10.1111/all.13209. View

17.

Hide M, Fukunaga A, Suzuki T, Nakamura N, Kimura M, Sasajima T . Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study. Allergol Int. 2022; 72(2):286-296. DOI: 10.1016/j.alit.2022.09.003. View

18.

Konstantinou G, Asero R, Maurer M, Sabroe R, Schmid-Grendelmeier P, Grattan C . EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009; 64(9):1256-68. DOI: 10.1111/j.1398-9995.2009.02132.x. View

19.

Itakura A, Tani Y, Kaneko N, Hide M . Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study. J Dermatol. 2018; 45(8):963-970. PMC: 6099381. DOI: 10.1111/1346-8138.14502. View

20.

Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K . Roles of omalizumab in various allergic diseases. Allergol Int. 2020; 69(2):167-177. DOI: 10.1016/j.alit.2020.01.004. View